Skip to content
Baltimore News Journal – Lifestyle
Author:
Electra Therapeutics
Electra Therapeutics Announces Initiation of a Phase 1 Trial of ELA822, a Novel SIRPγ-Specific Antibody Designed to Treat T Cell-Mediated Immune and Inflammatory Diseases
September 10, 2026
Electra Therapeutics Appoints Chris Clark, CFA, to Chief Financial Officer
September 9, 2026
Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell Malignancies
May 5, 2026